Conditions:  Recurrent Endometrial Adenocarcinoma;  Recurrent Endometrial Carcinoma;  Recurrent Endometrial Clear Cell Adenocarcinoma;  Recurrent Endometrial Dedifferentiated Carcinoma;  Recurrent Endometrial Endometrioid Adenocarcinoma;  Recurrent Endometrial Mixed Cell Adenocarcinoma;  Recurrent Endometrial Mucinous Adenocarcinoma;  Recurrent Endometrial Undifferentiated Carcinoma;  Recurrent Endometrioid Adenocarcinoma
Interventions: Â Biological:Â Ipilimumab; Â Biological:Â Nivolumab
Sponsors:  National Cancer Institute (NCI);  NRG Oncology
**RECRUITING NOW**
Interventions: Â Biological:Â Ipilimumab; Â Biological:Â Nivolumab
Sponsors:  National Cancer Institute (NCI);  NRG Oncology
**RECRUITING NOW**
Source: View full study details on ClinicalTrials.gov
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
